- December 15, 2024
- Category: What's New
EFOMP NEWSLETTER WINTER ISSUE 12/2024 | COMPANY MEMBER ΑRTICLE
End-to-end, versatile and vendor-neutral, PLANET® is recognized as the most comprehensive software solution for theranostics and patient-specific dosimetry applied to nuclear medicine.
From patient diagnostics, treatment planning to disease follow-up, the platform is specially designed to support multi-radionuclides, multi-therapies and multi-workflows, ensuring the best treatment tailored for each patient:
- Multi-radionuclides: all microspheres (90Y resin & glass, 166Ho), 177Lu, 131I and new additional beta-emitting isotopes;
- Multi-therapies: PSMA (prostate-specific membrane antigen), PRRT (peptide-receptor radionuclide therapy) for neuroendocrine tumor, 131I-mIBG for neuroblastoma, radioiodine treatment of hyperthyroidism, thyroid cancer, etc;
- Multi-workflows: SIRT (Selective Internal Radiation Therapy) and MRT (Molecular Radiation Therapy) dosimetry including 3D and Hybrid, single and multiple time points workflows.
Driven by new technological and clinical advancements, radiopharmaceutical therapy (RPT) is an evolving and promising modality of cancer treatment. However, achieving accurate, reproducible, and streamlined dosimetry remains challenging. Faced with both opportunities and challenges, DOSIsoft never stops to advance PLANET® by implementing novel quantitative imaging and radionuclide internal dosimetry methods.
Providing fast dosimetry computation, validated against Monte Carlo simulation
PLANET® is distinguished by its efficient and precise dose calculation engine. Clinically proven and validated by its multiple hospital centres, two algorithms are currently used in the software 1) Voxel S-values dose kernel convolution and 2) Local energy deposition method.
Both approaches are validated against precise Monte Carlo simulations, used to generate both kernels and reference dose computation specific to each isotope. 3D voxel-based dosimetry is made possible, enabling great personalization capability and adaptability to the different clinical workflows:
- SIRT (90Y & 166Ho): Pre & post -implantation dosimetry
- MRT (177Lu & 131I): Calculation of residence time and absorbed dose at voxel level
Enhancing automated dosimetry for optimized Theranostics
Access to fast and robust automatic segmentation methods is likely the key for clinics to easily handle SIRT and MRT dosimetry. Recently empowered by Artificial Intelligence (AI) tools, PLANET® enables further automation, standardization, and consistency – key requirements in the new Theranostics paradigm.
The features developed and incorporated in the new version (available soon) of PLANET® would help to provide seamless segmentation and reliable dosimetry
- Auto AI Segment: Automatic AI-powered segmentation of organs
- Auto Detect: One-click automatic segmentation of lesions
- Auto Fit: best fit automatically applied to pharmacokinetic modeling
Contributing to routine clinical dosimetry for personalized patient care
Currently, radionuclide-based therapies are limited to a few specialized centers with the need to increase clinical treatment capacities, and to widen the arsenal of radiotheranostics.
DOSIsoft, contributing partner to the EU-funded Thera4Care project – Theranostics Ecosystem For Personalized Care – plays a key role in the work package (WP7) dedicated to “Dosimetry” studies in order to advance novel dosimetric concepts & improved imaging equipment and especially contribute to one of the project’s overarching objectives: “enhancing clinical outcomes through AI-based imaging and personalized dosing protocols”.
During the next five years, DOSIsoft will focus its efforts on the further development of dosimetry software, providing standard protocols for imaging, simple and automatic dosimetry as well as dose adjustment ability:
- Enhanced dosimetry software for wider clinical use
- Support for new radionuclides
- Improved quantitative AI-based imaging and dosiomics
- Validated and quality-assured dosimetry workflows
Completely aligned with the development strategy of PLANET®, the achievement of these objectives will lead to the substantial improvements in clinical implementation of SIRT and MRT dosimetry. We believe that in the Era of Precision Oncology, PLANET® will become a reference dosimetry application to streamline and harmonize new radiotheranostics processes for optimized standard clinical practice.
About PLANET®: PLANET® Onco Dose Edition 3 is developed by DOSIsoft SA in France. Version 3.1 is FDA 510(k) cleared for 90Y Post-implantation and IIb class CE marked (MDD). The product or certain features may or may not be available for clinical use in any particular country.
About DOSIsoft – Founded in 2002, DOSIsoft designs, develops & delivers patient-specific imaging & dosimetry software solutions in Radiation Oncology & Nuclear Medicine to improve cancer patient safety & treatment quality. More than 20 years of innovation and R&D investments have led to world leading software used in over 600 hospital centres in 60 countries. Spin-off between Gustave Roussy and Institut Curie, DOSIsoft constantly innovates in partnership with the major cancer institutes and research centres in the world. It is now recognized as a key player in the dosimetry market. www.dosisoft.com